Imagine a tiny, smart sensor that acts like a high-tech smoke detector for your health, spotting warning signs in your blood or fluids instantly. Instead of waiting for lab results, doctors see these markers immediately through AR glasses or screens. It's like moving from a slow postal letter to an instant text message for critical patient data.
Medical professionals in ICUs and surgery rooms often face delays in receiving biomarker data, which slows down critical decision-making. Current monitoring often lacks the portability and real-time precision needed for immediate bedside intervention.
A suite of PoC tools including microneedle sensors for lactate/pH/CRP, contactless speckle plethysmography for heart vitals, and XR interfaces for real-time data visualization.
If you are a diagnostic developer dealing with slow lab turnaround times — this project developed energy-efficient biosensors and microneedles that provide real-time biomarker detection. This allows for immediate medical decision-making in surgery rooms and ICUs.
If you are a software provider dealing with complex data visualization for surgeons — this project developed intuitive extended reality interfaces. These tools visualize biomarker data in real-time to improve workflows in demanding clinical settings.
If you are a monitoring company dealing with the need for hospital-grade data at home — this project developed portable, interoperable PoC systems. These integrate vital sign monitoring with biomarker detection for use in the patient's home.
Based on available project data, specific pricing or cost structures are not provided.
The project mentions scalable SPR with energy-efficient electronic readouts and proposes lab-to-market paths, suggesting a focus on scalability.
Based on available project data, specific patent or licensing details are not listed, though the consortium aims for lab-to-market paths.
The system uses interoperable PoC designs and extended reality interfaces to integrate into surgery rooms, ICUs, and home-care environments.
The project period runs from 2023-12-01 to 2028-11-30, with clinical trials like STING already started.
The consortium is research-heavy with 11 partners across 7 countries, featuring a strong academic core of 4 universities and 4 research institutes. While the industry ratio is relatively low at 18% (2 companies, 2 of which are SMEs), the inclusion of diverse clinical settings (surgery, ICU, home) suggests a strong focus on practical validation over pure theory.
Contact Universiteit Twente (NL) for partnership inquiries.
Contact SciTransfer to explore licensing opportunities for these PoC biosensors.
